IDEXX Laboratories, Inc. $IDXX Stock Sold by Illinois Municipal Retirement Fund

Illinois Municipal Retirement Fund lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 17.1% in the third quarter, HoldingsChannel reports. The firm owned 9,209 shares of the company’s stock after selling 1,900 shares during the period. Illinois Municipal Retirement Fund’s holdings in IDEXX Laboratories were worth $4,809,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. 71 West Capital Partners grew its stake in shares of IDEXX Laboratories by 11.9% in the 3rd quarter. 71 West Capital Partners now owns 1,288 shares of the company’s stock valued at $673,000 after buying an additional 137 shares during the period. Gryphon Financial Partners LLC purchased a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at approximately $339,000. AlphaCore Capital LLC raised its position in shares of IDEXX Laboratories by 1,029.5% during the 3rd quarter. AlphaCore Capital LLC now owns 2,338 shares of the company’s stock valued at $1,221,000 after buying an additional 2,131 shares during the period. Fulcrum Asset Management LLP lifted its holdings in IDEXX Laboratories by 9.9% in the third quarter. Fulcrum Asset Management LLP now owns 1,159 shares of the company’s stock valued at $618,000 after acquiring an additional 104 shares during the last quarter. Finally, Bryn Mawr Trust Advisors LLC acquired a new position in IDEXX Laboratories in the third quarter valued at approximately $5,216,000. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other news, EVP Sharon E. Underberg sold 8,906 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total value of $6,132,582.54. Following the sale, the executive vice president directly owned 7,169 shares in the company, valued at approximately $4,936,501.71. This trade represents a 55.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel M. Junius sold 1,200 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 4th. The shares were sold at an average price of $704.07, for a total value of $844,884.00. Following the completion of the transaction, the director owned 2,361 shares of the company’s stock, valued at approximately $1,662,309.27. This trade represents a 33.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 41,428 shares of company stock valued at $28,567,934. Corporate insiders own 0.79% of the company’s stock.

Wall Street Analysts Forecast Growth

IDXX has been the subject of several recent analyst reports. Citigroup raised their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. KeyCorp started coverage on IDEXX Laboratories in a research note on Monday, October 12th. They issued a “sector weight” rating on the stock. UBS Group increased their price target on IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a report on Tuesday, November 3rd. Barclays cut their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. Finally, Jefferies Financial Group lowered their target price on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating for the company in a research note on Tuesday, October 20th. Seven investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $717.27.

Get Our Latest Research Report on IDXX

IDEXX Laboratories Stock Performance

IDXX opened at $704.23 on Monday. IDEXX Laboratories, Inc. has a 52 week low of $500.61 and a 52 week high of $769.98. The business has a fifty day simple moving average of $562.41 and a 200-day simple moving average of $573.52. The firm has a market cap of $55.48 billion, a P/E ratio of 47.49 and a beta of 1.55. The company has a quick ratio of 0.88, a current ratio of 1.19 and a debt-to-equity ratio of 0.16.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.71 by $0.25. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the prior year, the company earned $3.22 EPS. IDEXX Laboratories’s revenue was up 9.9% on a year-over-year basis. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current year.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

Read More

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.